Ondavell

Quick links to important sections

Ondavell

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondavell

Quick Facts

Property Description
Active ingredient Ondansetron (INN)
Form Tablet (ODT, film-coated), Oral Solution, Injectable Solution
Pharmacological class Serotonin 5-HT3 Receptor Antagonist
Common purpose Prevention and relief of nausea and vomiting
Origin Synthetic Compound

What Type of Medicine is Ondavell (Ondansetron)?

Ondavell is a prescription-only antiemetic medicine primarily used to counteract symptoms of nausea and vomiting, distinguished by its highly selective pharmacological action. Its active component, Ondansetron (the International Nonproprietary Name), is a synthetic compound that functions as a potent blocker of specific chemical signals in the nervous system. The classification of Ondansetron as a Serotonin 5-HT3 receptor antagonist is globally recognized. This pharmacological selectivity involves a focused effect on receptors involved in the emetic response. This mechanism involves the drug selectively targeting and occupying the 5-HT3 receptors, which are key sites both in the gut and centrally within the chemoreceptor trigger zone (CTZ). By interfering with the action of the neurotransmitter serotonin at these specific sites, the medicine provides a focused intervention to interrupt the reflex responsible for nausea and emesis.

Composition, Forms, and General Purpose

The drug Ondavell is formulated as a single active ingredient product, relying exclusively on the therapeutic action of Ondansetron for its effects against nausea and vomiting. This medicine is considered an essential pharmaceutical, as it is included on the international List of Essential Medicines. This indicates that the compound is considered critical for addressing priority health care needs globally. Ondavell is supplied for both oral administration and parenteral administration to accommodate varying clinical needs, particularly in contexts like managing discomfort following surgical procedures. Available preparations include the standard film-coated tablet, a rapidly dissolving Orally Disintegrating Tablet (ODT), an oral solution, and an injectable solution provided in an aqueous solution base. The availability of the ODT form is a differentiating feature for patients who may have difficulty swallowing. The overarching therapeutic purpose of the drug is to powerfully counteract the signals that promote the experience of nausea and the physical act of vomiting.

Regulatory References

  1. World Health Organization’s List of Essential Medicines

What side effects are possible with Ondavell?

Possible side effects and safety information

The safety profile of Ondavell (Ondansetron) is formally classified by regulatory authorities based on the frequency and type of documented adverse reactions. These effects are grouped according to the physiological systems involved, providing a structured overview of the medicine's risk characteristics.

Frequency-Classified Adverse Reactions

Adverse reactions are documented according to their observed incidence rate, with headache being listed as a Very Common event. Effects classified as Common include constipation, a sensation of warmth or flushing, and local reactions at the intravenous injection site. Less frequent, or Uncommon, reactions involve seizures and various movement disorders, as well as arrhythmias and asymptomatic increases in liver function tests.

Serious Adverse Reactions

Regulatory documentation highlights the potential for serious adverse reactions that require specific consideration. These include the risk of QTc prolongation and Torsade de Pointes, which are relevant for individuals with underlying cardiac risk factors. Other documented serious effects include Serotonin Syndrome—associated with the co-administration of other serotonergic agents—and immediate hypersensitivity reactions, such as anaphylaxis. Myocardial Ischemia and severe bullous skin reactions are also included in the serious adverse reaction reporting.

Population-Specific Safety and Limitations

Safety characteristics are noted for specific populations; for instance, drug clearance is significantly reduced and the half-life is prolonged in patients with moderate to severe hepatic impairment. For the pediatric population and older adults, the adverse event profile is generally comparable to that observed in younger adults. The medication is officially contraindicated for use with Apomorphine due to the risk of profound hypotension. Furthermore, official labeling states that the medicine may mask symptoms of progressive ileus or gastric distension in some patients.

Overdose and Emergency Response

Overdose involving Ondavell is characterized by specific documented effects on the cardiovascular and nervous systems, as stated in regulatory prescribing information. Manifestations reported in overdose cases include neurological signs such as somnolence, agitation, seizure activity, myoclonic movements, and hyperreflexia. Transient symptoms like sudden blindness (amaurosis) and severe constipation have also been observed.

The most serious documented risks involve the cardiovascular system, specifically dose-dependent QT interval prolongation and post-marketing reports of Torsade de Pointes, a potentially fatal ventricular arrhythmia. Furthermore, cases consistent with Serotonin Syndrome, which includes features like altered mental status and autonomic instability, have been reported following overdose, particularly in young children.

Given the serious nature of these potential outcomes, immediate medical attention must be sought if an overdose is suspected. Clinical management requires appropriate supportive therapy under professional supervision. Due to the cardiac risks, ECG monitoring is explicitly recommended for all patients following a suspected overdose to assess the degree of QTc prolongation. The official regulatory documents confirm that no specific antidote is known for Ondavell overdose, thus emphasizing the critical role of immediate supportive clinical care.

Therapeutic Uses of Ondavell

What Ondavell Treats: Main Uses and Benefits

Ondavell is an antiemetic medication used for supportive management in clinical settings marked by heightened patient distress, particularly symptoms related to systemic imbalance. The medicine is commonly used to prevent sickness associated with major interventions. The primary therapeutic benefit may be part of symptomatic management that focuses on the prevention and relief of pronounced symptoms, contributes to improved comfort and supports the patient during difficult episodes during critical phases of care.

Primary Symptomatic Domains

Ondavell is applied across domains where short-term symptomatic assistance is appropriate, including conditions characterized by periods of heightened symptoms such as chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and postoperative nausea and vomiting (PONV).

It is applied in addressing symptom clusters that may become intense or disruptive, helping patients cope more steadily with their prescribed regimens and contributing to easing the overall symptom load.

“This supportive relief is considered relevant in contexts involving heightened systemic burden, especially where acute symptom manifestations interfere with daily functioning.”

In specific acute clinical scenarios, the medication may assist with maintaining a sense of stability for vulnerable groups, such as pediatric patients (aged six months and older) with severe, disruptive emesis.


Quick Fact: Relief for Acute and Delayed Emesis
Primary Symptom Nausea and Vomiting (Emesis)
Typical Contexts Oncological Treatment, Surgical Recovery
Benefit Focus Symptom prevention and supportive relief

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Ondavell (Ondansetron) is strictly defined by regulatory health authorities based on a patient's medical history, age, and physiological status.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to ondansetron or any component of the formulation. It is also strictly prohibited for concurrent use with apomorphine. Furthermore, patients diagnosed with congenital Long QT syndrome should avoid this medicine due to the specific cardiac risk identified in regulatory labeling.

Eligibility Domain Official Regulatory Status
Severe Restriction Severe hepatic impairment requires the total daily dose not to exceed 8 mg. Patients with other cardiac risk factors (e.g., heart failure, electrolyte abnormalities) must use the medicine with caution.
Age Group Limits The minimum approved age is 6 months and older for Chemotherapy-Induced Nausea and Vomiting (CINV). Approval for Postoperative Nausea and Vomiting (PONV) extends to children aged 1 month and older. Use in infants under one month is not approved.
Maternal Status Use is not recommended during the first trimester of pregnancy due to regulatory warnings, and breastfeeding is also not recommended.

Adults and older adults are generally eligible for use. The Orally Disintegrating Tablet (ODT) formulation contains phenylalanine, a necessary consideration for patients with Phenylketonuria. No dosage alteration is typically required for patients with renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ondavell's interaction profile is officially documented based on specific pharmacokinetic and pharmacodynamic patterns.

Interaction Classification Interacting Medicines or Substances Regulatory Outcome
Formal Contraindication Apomorphine Co-administration is prohibited due to the risk of profound hypotension and loss of consciousness.
Pharmacodynamic Risk Serotonergic Drugs (e.g., SSRIs, Tramadol) Increased risk of Serotonin Syndrome due to additive effects.
Pharmacodynamic Risk Other QT Prolonging Drugs Associated with an increased risk of QT interval prolongation.
Pharmacokinetic Effect CYP3A4 Inducers (e.g., Phenytoin, Rifampin) These substances significantly increase the clearance of Ondansetron, resulting in decreased blood concentrations.

Ondansetron is a known substrate for multiple hepatic Cytochrome P450 enzymes, chiefly CYP3A4, which serves as the mechanistic basis for the documented pharmacokinetic interactions. Interaction-related restrictions also apply to specific populations. Patients with severe hepatic impairment exhibit substantially decreased clearance of the medicine, which alters the maximum recommended total daily dose. Furthermore, a timing-based constraint exists for intravenous administration: repeat doses in the elderly must be given no less than four hours apart. A product-specific restriction notes that the Orally Disintegrating Tablet (ODT) contains Phenylalanine, a specific consideration for individuals with Phenylketonuria (PKU).

Mechanism of Action

Ondavell is an antagonist molecule that selectively targets the 5-HT3 receptor in both the peripheral and central nervous systems.


Biological Targets and Interaction

The primary biological targets are 5-HT3 receptors located on the afferent nerve terminals of the vagus nerve in the gastrointestinal (GI) tract and centrally within the chemoreceptor trigger zone (CTZ) in the area postrema of the medulla. Ondavell competitively binds to the extracellular site of the ligand-gated ion channel structure of the 5-HT3 receptor, preventing the endogenous neurotransmitter serotonin (5-HT) from binding and activating the receptor.


Intracellular and System-Level Modulation

This antagonistic interaction blocks the inward flux of cations, which normally results in neuronal depolarization and subsequent signal propagation. Peripherally, the blockade inhibits the activation of vagal afferents stimulated by GI-released serotonin. Centrally, it prevents the over-stimulation of 5-HT3 receptors within the CTZ. The resulting modulation is a decrease in the neural signal transmission from the periphery to the nucleus tractus solitarius (NTS) and a reduced excitability in the central medullary pathways. This integrated system-level effect leads to a systemic inhibition of the afferent neural signaling associated with the emetic reflex arc.

Dosage and Administration Information

Ondavell (Ondansetron) administration is governed by official protocols designed for short-term, acute clinical use and is tailored to the nature of the event causing the symptoms. The medicine is primarily administered via the oral route (tablets or solution) or parenterally through intravenous (IV) or intramuscular (IM) injection to accommodate different clinical needs. The timing is crucial, as the drug is typically used prophylactically, often 30 minutes before the start of chemotherapy or 1 hour before inducing anesthesia for surgical procedures.

The standard dosing regimens are fixed and vary based on the anticipated emetogenic risk. For instance, prevention of nausea associated with Highly Emetogenic Chemotherapy (HEC) may involve a single 24 mg oral dose. In contrast, Postoperative Nausea and Vomiting (PONV) is addressed with a single 4 mg dose given IV or IM. Oral administration is generally unaffected by food and can be taken as required by the regimen.

For the injectable form, the drug often requires dilution in a compatible intravenous fluid for CINV doses and must be infused over a defined duration. When administered as a single 4 mg IV dose, the injection is given slowly, typically over 2 to 5 minutes. Usage is generally limited to a course of 1 to 5 days following the completion of the inciting treatment. A critical labeled instruction for specific populations dictates that patients with severe hepatic impairment must not exceed 8 mg as a total daily dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ondavell

The clinical evaluation of Ondavell (Ondansetron) was observed in numerous studies, including randomized controlled trials (RCTs) and systematic reviews. These studies contribute to understanding what has been observed so far regarding the use of the medicine across different conditions. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.


Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

The evidence for CINV is primarily documented by RCTs and comprehensive meta-analyses. These studies focused on outcomes related to physical discomfort during the acute phase (within 24 hours after treatment) and the delayed phase (up to three to five days afterward). Research examined how symptoms evolved in the observed populations, monitoring both the complete absence of vomiting and how patients reported their experience with nausea. Findings describe patterns observed in the studies related to the measured changes in these episodes.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Ondavell was studied for use in PONV, which involves conditions associated with acute or disruptive episodes following surgery. The research has included randomized, controlled trials focusing on the short-term recovery period. Studies monitored episodic changes by measuring the rate of vomiting and nausea incidence. Findings describe group patterns related to these outcomes, as research was structured to compare groups who received Ondavell against a comparator or an inactive substance.


Evidence in Special Populations

Research has explored the use in pediatric patients (children as young as one to six months) for both CINV and PONV. Ondavell was also studied for use in pediatric patients with acute gastroenteritis, often focusing on outcomes related to measured changes in vomiting episodes. These findings were mixed regarding whether its use was associated with differences in hospital readmission rates, representing a specific example where certainty remains low due to inconsistent results.

Areas of Research Uncertainty and Study Gaps

The majority of the evidence is relevant in trials assessing short-term or episodic symptom patterns, meaning long-term effects are not fully established. Follow-up durations were limited to the immediate acute events. Data for certain groups remain insufficient, and evidence quality varies across studies, especially regarding the volume of comparative evidence for radiation-induced nausea and vomiting (RINV).

Key Studies & References

  1. Ondansetron - StatPearls - NCBI Bookshelf
  2. Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ondavell (FAQ)

Q: How long does it usually take to feel the effects of Ondavell?

A: Official information indicates that the active component of Ondavell typically reaches its peak concentration in the bloodstream approximately 1.5 to 2.2 hours after taking an oral tablet. This point represents the maximum absorption of the medicine. The time it takes for an individual to notice the intended effect may vary.

Q: Is Ondavell the same type of medicine as [A competitor drug name]?

A: Ondavell belongs to a specific group of medicines known as Serotonin 5-HT3 receptor antagonists. This means that it works by blocking the action of the chemical messenger serotonin at certain sites in the body. Other medicines within the same pharmacological class may share this basic mechanism of action, but their specific properties or formulations can be different.

Q: Does Ondavell cause tiredness or grogginess?

A: In clinical trials, tiredness or grogginess were not classified as common or very common side effects. However, official post-marketing reports have included occurrences of drowsiness and sedation. If a patient experiences these effects, caution is described as necessary when performing tasks requiring full alertness.

Q: Are there any specific foods or drinks I should avoid while taking Ondavell?

A: According to the official administration instructions, the oral forms of Ondavell can generally be taken with or without food. No specific foods or non-alcoholic beverages are listed in regulatory documents as needing to be strictly avoided.

Q: What happens if I miss a dose of Ondavell?

A: Patient guidelines often describe taking the missed dose as soon as it is remembered. If it is nearly time for the next scheduled dose, guidelines describe only taking the next scheduled dose. Official instructions advise against taking extra doses to make up for a missed one.

Q: Why is Ondavell given for [a secondary, less common use]?

A: The primary official uses for Ondavell are for preventing nausea and vomiting caused by chemotherapy (CINV) and postoperative nausea and/or vomiting (PONV). Official regulatory documents may also list it for use against nausea and vomiting associated with radiation therapy, reflecting its ability to counteract different stimuli that trigger the emetic response.

Q: Do I need any special tests while I am taking Ondavell?

A: The medicine carries a warning about a possible rare side effect called QTc prolongation, which involves changes to the electrical activity of the heart. Official documents describe that monitoring of electrocardiograms (ECGs) may be considered for individuals with certain cardiac risk factors.

Q: Is Ondavell habit-forming or addictive?

A: Ondavell (ondansetron) is an antiemetic medicine. Regulatory agencies do not classify this medicine as a controlled substance, meaning it is not considered to have a risk for dependence or abuse.

Q: Does taking Ondavell make you gain or lose weight?

A: Weight changes, including both weight gain and weight loss, are not listed among the common or very common adverse reactions documented in clinical studies or official post-marketing reports for this medicine.

Q: Why do some people stop taking Ondavell?

A: Based on regulatory data, reasons for discontinuation often involve the occurrence of documented side effects, such as headache or constipation. Another reason is the completion of the prescribed short duration of therapy, as the medicine is typically used for a period of 1 to 5 days following the inciting event.

Q: What evidence exists for using Ondavell long-term?

A: Regulatory evidence is predominantly based on clinical trials that assessed the medicine's effects over short periods, particularly during or immediately after chemotherapy or surgery. Information regarding potential effects associated with long-term use that extends beyond the immediate acute event is not fully established in the existing regulatory research overview.

Q: How is Ondavell different from other drugs in its class?

A: While all medicines in the Serotonin 5-HT3 antagonist class share a basic action, they can differ in specifics. Distinguishing features of Ondavell may include its various formulation options (e.g., ODT), its pharmacokinetic profile (how the body processes it), and its specific potency on the targeted receptor.

Q: Does the time of day I take Ondavell matter?

A: Official administration instructions prioritize the timing relative to the medical event being prevented. For example, it is taken prophylactically (in advance) 30 minutes before the start of chemotherapy or before inducing anesthesia, rather than being linked to a fixed time of day like morning or evening.

Q: How can I tell if Ondavell is actually working for me?

A: The intended effect of the medicine is to counteract signals that cause nausea and vomiting. Effectiveness is assessed in clinical studies by measuring key outcomes such as the complete absence of vomiting episodes and the reduction of the patient's reported experience of nausea.

Q: Is there a maximum amount of time I can take Ondavell?

A: Regulatory instructions generally limit the use of the medicine to a short course, typically 1 to 5 days following the completion of the inciting medical treatment, such as a chemotherapy session.

Q: What happens to Ondavell in the body?

A: After being absorbed, Ondavell is primarily metabolized (broken down) in the liver by specific enzymes, mainly CYP3A4. Once processed, the resulting components are then cleared from the body through both urine and feces.

Q: Can I crush or split my Ondavell tablets?

A: Official instructions for the Orally Disintegrating Tablet (ODT) formulation specify that it should be allowed to dissolve on the tongue before being swallowed. This indicates that crushing or splitting is not the officially labeled or recommended method for using this form of the medicine.

Q: Are there any supplements that interact with Ondavell?

A: Official regulatory warnings list interactions with prescription and over-the-counter medicines that affect heart rhythm or serotonin levels. Specific herbal or dietary supplements are not individually named in the regulatory interaction table.

Q: What should I do if I feel dizzy after taking Ondavell?

A: Dizziness is a reported side effect of Ondavell. Official guidance highlights the necessity of seeking immediate medical attention if dizziness is severe, sudden, or accompanied by other serious signs, such as a fast heart rate, fainting, or chest pain. This is due to the low risk of QTc prolongation.

Q: Why is Ondavell sometimes prescribed at a lower starting amount?

A: Regulatory instructions require that individuals diagnosed with severe hepatic impairment (severe liver problems) receive a reduced maximum total daily amount. This adjustment is necessary because the liver is essential for clearing the medicine from the body, and impairment results in slower processing.

Q: Does Ondavell need to be stored in the refrigerator?

A: The oral forms (tablets, solution) should be stored at Controlled Room Temperature (20°C to 25°C) and protected from light and moisture. Injectable vials may have different storage requirements and may be kept refrigerated or at room temperature, depending on the specific product label.

Q: Can Ondavell affect my ability to drive or operate machinery?

A: Official documentation advises that the medicine can cause certain side effects, such as dizziness or temporary visual disturbances. These effects could potentially impact a person's ability to drive or safely operate machinery, and appropriate caution is described as necessary.

Q: Is it true that Ondavell is used in combination with other drugs sometimes?

A: Yes, regulatory documents describe that for certain high-risk situations, such as highly emetogenic chemotherapy, Ondavell is prescribed as part of a standard prophylactic regimen used in combination with other antiemetic agents to maximize preventative effect.

Q: Why does Ondavell have a warning about [a specific, common side effect]?

A: Warnings are included in official labeling when the medicine is documented to carry a risk of specific, sometimes serious, adverse reactions. For instance, warnings about QTc prolongation are necessary because the medicine may affect heart conduction. Warnings about Serotonin Syndrome exist because the medicine's mechanism can interact additively with other serotonergic agents.

How should Ondavell be stored and disposed of?

How to Store and Dispose of Ondavell?

Ondavell (ondansetron) must be stored and handled according to the official requirements detailed on the medicine's regulatory labeling.

Storage Conditions

Oral forms (tablets, ODTs, solution) must be stored at a Controlled Room Temperature of 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture, and tablets should be retained in the original container. The oral solution must be protected from freezing. Injectable vials may also be stored refrigerated (2 C to 8 C) and must be kept in the carton until use. Once the injection is diluted for use, it has a specified stability limit (e.g., 48 hours).

Safety and Disposal

All forms of the medicine must be stored out of the sight and reach of children. Unused or expired Ondavell must be disposed of according to local regulations, such as a drug take-back program. Disposal must not be made via wastewater or flushed down a toilet unless governmental instructions specifically permit it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondavell found in:

A-Z Index: